Research & Development

FDA Approves Journavx: A New Non-Opioid Solution for Acute Pain
Research & Development FDA Approves Journavx: A New Non-Opioid Solution for Acute Pain

On Thursday, the Food and Drug Administration approved Journavx, a highly anticipated non-opioid pain medication developed by Vertex Pharmaceuticals, marking a significant milestone in the effort to shift pain treatment away from opioids. This new drug has been initially approved to treat acute

How Is Climate Change Increasing Urological Diseases and Cancers?
Research & Development How Is Climate Change Increasing Urological Diseases and Cancers?

Climate change is an urgent global issue with far-reaching impacts on human health. Among the many health concerns exacerbated by climate change, urological diseases and cancers are increasingly coming into focus. This article explores the intricate connections between climate change and the rising

Do Caregiver Support Programs Enhance Dementia Patient Outcomes?
Research & Development Do Caregiver Support Programs Enhance Dementia Patient Outcomes?

In the challenging landscape of dementia care, caregivers are the unsung heroes who shoulder the burden of looking after their loved ones. The emotional, physical, and financial stress experienced by caregivers often goes unnoticed, despite playing a crucial role in the well-being of dementia

Is T-VEC an Effective Neoadjuvant Therapy for Basal Cell Carcinoma?
Research & Development Is T-VEC an Effective Neoadjuvant Therapy for Basal Cell Carcinoma?

Basal cell carcinoma (BCC) is the most common cancer worldwide, with its incidence doubling over the past 20 years. Traditional treatments, primarily surgical excision, come with a recurrence risk and potential complications. This article explores the potential of Talimogene laherparepvec (T-VEC),

AI Tool MUNIS Revolutionizes Epitope Prediction for Vaccine Development
Research & Development AI Tool MUNIS Revolutionizes Epitope Prediction for Vaccine Development

A significant breakthrough in vaccine development has been achieved by a collaboration between the Ragon Institute and the Jameel Clinic at MIT, as they unveil MUNIS, a deep learning tool designed to accurately predict CD8+ T cell epitopes. This innovative tool promises to accelerate vaccine

Dual Inhibition of MYCN and MDM2: A New Hope for Cancer Therapy
Research & Development Dual Inhibition of MYCN and MDM2: A New Hope for Cancer Therapy

In the relentless pursuit of enhanced cancer treatments, recent research has shed light on the dual inhibition of MYCN and MDM2 as a promising strategy. Both MYCN and MDM2 are vital oncogenes implicated in various tumorigenic processes. Their simultaneous targeting might revolutionize the

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later